Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALE1 in Healthy Subjects and Patients With Hypophosphatasia
NCT07179640Phase 2Recruiting
- Sponsor
- Alesta Therapeutics
- Start
- Sep 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of ALE1 in hypophosphatasia (HPP), sponsored by Alesta Therapeutics. Started Sep 2025; status: recruiting.
02
Drugs
ALE1
03
Conditions
hypophosphatasia (HPP)
Beyond the preview
Go deeper on NCT07179640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07179640.